Active, not recruitingPhase 4NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib
Novartis Pharmaceuticalsn = 1347 Jul 2022 to est. 14 Aug 2030
Metastatic Breast Cancer
Goserelin / Studies
Synthetic analog · 10 amino acids · 1,269.4 Da
Goserelin studies and research data
PepBank has 119 goserelin studies with results. 116 of them gave goserelin, with 583 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 583 results and 1,014 papers. Newer studies from Europe PMC
Results in people
505
87% of 583 results
Results in animals
72
12% of 583 results
Results in lab cells
6
1% of 583 results
From computer models
0
0% of 583 results
The molecule
Goserelin identity
Identifiers, parent molecule, targets and development stage, from curated data.
Goserelin is a GnRH agonist analog with D-Ser(O-tert-butyl) at position 6 and azaglycinamide at position 10. The implant provides sustained exposure.
- Kind
- Synthetic analog · 10 residues
- Identifiers
- ChEMBLCHEMBL1201247 (opens in a new tab)PubChem CID5311128 (opens in a new tab)UNII0F65R8P09N (opens in a new tab)DrugBankDB00014 (opens in a new tab)CAS65807-02-5
- Parent
- Analog of GonadorelinGoserelin is an analog of gonadorelin with D-Ser(O-tert-butyl) at position 6 and azaglycinamide at position 10. UniProt P01148 identifies the human GnRH precursor.
- Development
- Approved in the US and EU (Zoladex)An approved medicinal product exists. Availability and other indications can differ. Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| Gonadotropin-releasing hormone receptorGNRHRP30968 (opens in a new tab) | Agonist | Official prescribing information, mechanism of actionSource (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
10 amino acids · 3 modifications
Residues 1 to 10:
HWSYLRP
Alignment to Gonadorelin
Calculated from the two sequences. Curated notes are shown as given.
7 of 10 aligned residues identical (70%) · 1 substitution · 2 non-canonical residues · Gonadorelin 1–10
- Top row: Gonadorelin (parent)
- Bottom row: Goserelin
HWSYLRP
- Same as parent
- Substituted
- Non-canonical or D-form
- Added
- Gap
- Modified side chain or end
Differences from the parent
- 1Parent 1 · analog 1Xaa → Glu · SubstitutionPyro-Glu
- 2Parent 6 · analog 6Gly → Ser · Non-canonical residueO-tert-butyl-D-Ser
- 3Parent 10 · analog 10Gly → Azagly · Non-canonical residueAzagly
Basis: Goserelin is an analog of gonadorelin with D-Ser(O-tert-butyl) at position 6 and azaglycinamide at position 10. UniProt P01148 identifies the human GnRH precursor.
Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.
Properties
From identity sources
- Formula
- C59H84N18O14
- Molecular weight
- 1,269.4 g/mol
- Monoisotopic mass
- 1,268.6414 Da
- GSRS UNII 0F65R8P09N(opens in a new tab)retrieved 2026-10-27
- PubChem CID 5311128(opens in a new tab)retrieved 2026-10-27
- Curated Zoladex US label(opens in a new tab)retrieved 2026-10-27
Calculated from the sequence
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
- Average mass
- Not calculated
- Monoisotopic mass
- Not calculated
- Isoelectric point (pI)
- Not calculated
- Net charge at pH 7.4
- Not calculated
- GRAVY (hydropathy)
- Not calculated
- Extinction coefficient, 280 nm (Cys reduced)
- 6,990 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
- Instability index
- Not calculated
- Aliphatic index
- Not calculated
- Boman index
- Not calculated
- Hydrophobic moment (μH)
- Not calculated
- 1 non-canonical residue (X) is not included in calculated values.
- Not included: other modification. Mass, charge and pI are not calculated; use the identity-source values.
- The N-terminal group is not modeled.
- The C-terminal group is not modeled.
- Defined and validated for proteins; use with care for short peptides.
- Assumes an ideal alpha helix. Many short peptides are not helical.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
Net charge by pH
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
Composition
- Hydrophobic10% (1)L
- Aromatic20% (2)W Y
- Positive20% (2)H R
- Negative10% (1)E
- Polar20% (2)S
- Special10% (1)P
- Non-canonical10% (1)X
10 residues. Each residue counts in one class; F and W count as aromatic.
A Ala0 · 0%
I Ile0 · 0%
L Leu1 · 10%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp1 · 10%
Y Tyr1 · 10%
H His1 · 10%
K Lys0 · 0%
R Arg1 · 10%
D Asp0 · 0%
E Glu1 · 10%
N Asn0 · 0%
Q Gln0 · 0%
S Ser2 · 20%
T Thr0 · 0%
C Cys0 · 0%
G Gly0 · 0%
P Pro1 · 10%
X Xaa1 · 10%
3D structure
PredictedAlphaFold DB · P01148
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
2D structure
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 5311128(opens in a new tab)
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6Results by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data